These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37019180)

  • 21. The effects of intermittent fasting diet in comparison with low-calorie diet on lipid profile, glycemic status, and liver fibrosis in patients with non-alcoholic fatty liver (NAFLD): a study protocol for a randomized controlled clinical trial.
    Karimi M; Nejad MM; Akhgarjand C; Sohrabpour AA; Poustchi H; Imani H; Mohammadi H
    BMC Nutr; 2023 Dec; 9(1):145. PubMed ID: 38066628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of lifestyle behaviors with non-alcoholic fatty liver disease and advanced fibrosis detected by transient elastography among Hispanic/Latinos adults in the U.S.
    Heredia NI; Zhang X; Balakrishnan M; Hwang JP; Thrift AP
    Ethn Health; 2023 Feb; 28(2):299-312. PubMed ID: 35067116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials.
    Lee D; Chiavaroli L; Ayoub-Charette S; Khan TA; Zurbau A; Au-Yeung F; Cheung A; Liu Q; Qi X; Ahmed A; Choo VL; Blanco Mejia S; Malik VS; El-Sohemy A; de Souza RJ; Wolever TMS; Leiter LA; Kendall CWC; Jenkins DJA; Sievenpiper JL
    Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety analysis of Danggui Shaoyao Powder for the treatment of non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled clinical trial.
    Huang Q; An Z; Xin X; Sun Q; Gao S; Lv S; Xu X; Yang S; Lu F; Yuan J; Zhao Y; Hu Y; Liu P; Feng Q
    BMC Complement Med Ther; 2023 Apr; 23(1):126. PubMed ID: 37076843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial.
    Sun Y; Chen G; Chen S; Wang Y; Hu Y; Zhao Y
    Trials; 2022 Jun; 23(1):455. PubMed ID: 35655225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dietary determinants of hepatic fat content and insulin resistance in overweight/obese children: a cross-sectional analysis of the Prevention of Diabetes in Kids (PREDIKID) study.
    Arenaza L; Medrano M; Oses M; Huybrechts I; Díez I; Henriksson H; Labayen I
    Br J Nutr; 2019 May; 121(10):1158-1165. PubMed ID: 30832745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
    Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ
    Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in Biomarkers of Non-Alcoholic Fatty Liver Disease (NAFLD) upon Access to Avocados in Hispanic/Latino Adults: Secondary Data Analysis of a Cluster Randomized Controlled Trial.
    Pacheco LS; Bradley RD; Anderson CAM; Allison MA
    Nutrients; 2022 Jun; 14(13):. PubMed ID: 35807924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of aerobic exercise and low carbohydrate diet on pre-diabetic non-alcoholic fatty liver disease in postmenopausal women and middle aged men--the role of gut microbiota composition: study protocol for the AELC randomized controlled trial.
    Liu WY; Lu DJ; Du XM; Sun JQ; Ge J; Wang RW; Wang R; Zou J; Xu C; Ren J; Wen XF; Liu Y; Cheng SM; Tan X; Pekkala S; Munukka E; Wiklund P; Chen YQ; Gu Q; Xia ZC; Liu JJ; Liu WB; Chen XB; Zhang YM; Li R; Borra RJ; Yao JX; Chen PJ; Cheng S
    BMC Public Health; 2014 Jan; 14():48. PubMed ID: 24438438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised controlled trial of a Mediterranean Dietary Intervention for Adults with Non Alcoholic Fatty Liver Disease (MEDINA): study protocol.
    Papamiltiadous ES; Roberts SK; Nicoll AJ; Ryan MC; Itsiopoulos C; Salim A; Tierney AC
    BMC Gastroenterol; 2016 Feb; 16():14. PubMed ID: 26831892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease.
    Hsu CC; Ness E; Kowdley KV
    Adv Nutr; 2017 Mar; 8(2):253-265. PubMed ID: 28298270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial.
    Janczyk W; Socha P; Lebensztejn D; Wierzbicka A; Mazur A; Neuhoff-Murawska J; Matusik P
    BMC Pediatr; 2013 May; 13():85. PubMed ID: 23702094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of a Mediterranean diet
    Akbulut UE; Isik IA; Atalay A; Eraslan A; Durmus E; Turkmen S; Yurttas AS
    Int J Food Sci Nutr; 2022 May; 73(3):357-366. PubMed ID: 34565261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of a low free sugar diet on the management of nonalcoholic fatty liver disease: a randomized clinical trial.
    Khodami B; Hatami B; Yari Z; Alavian SM; Sadeghi A; Varkaneh HK; Santos HO; Hekmatdoost A
    Eur J Clin Nutr; 2022 Jul; 76(7):987-994. PubMed ID: 35058605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents - rationale and protocol.
    Wicklow B; Wittmeier K; T' Jong GW; McGavock J; Robert M; Duhamel T; Dolinsky VW
    Biochem Cell Biol; 2015 Oct; 93(5):522-30. PubMed ID: 26305052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dietary and sociodemographic factors associated with nonalcoholic fatty liver in obese pediatric patients.
    León-Plascencia M; Larrosa-Haro A; Romero-Velarde E; Bravo-Núñez EC; López-Marure E
    Rev Gastroenterol Mex (Engl Ed); 2021; 86(3):236-243. PubMed ID: 34210457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-Alcoholic Fatty Liver Disease in Overweight Children: Role of Fructose Intake and Dietary Pattern.
    Nier A; Brandt A; Conzelmann IB; Özel Y; Bergheim I
    Nutrients; 2018 Sep; 10(9):. PubMed ID: 30235828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between excessive dietary fructose consumption and paediatric fatty liver disease.
    DiStefano JK; Shaibi GQ
    Pediatr Obes; 2021 Jun; 16(6):e12759. PubMed ID: 33305889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model.
    Vreman RA; Goodell AJ; Rodriguez LA; Porco TC; Lustig RH; Kahn JG
    BMJ Open; 2017 Aug; 7(8):e013543. PubMed ID: 28775179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver fat as a dietary target by Chinese Medical Nutrition Therapy (CMNT) diet for treating type 2 diabetes with non-alcoholic fatty liver disease: study protocol for a randomised controlled trial.
    Luo W; Xiao Z; Yang X; Wu R; Li J; Yu Z; Guo S; Nie B; Liu D
    BMJ Open; 2024 Apr; 14(4):e081263. PubMed ID: 38684277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.